Compare Bank of America Corp (BAC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs Recursion Pharmaceuticals Inc — how do they compare? Bank of America Corp trades at $61.66 (market cap $425.43B), while Recursion Pharmaceuticals Inc trades at $3.4 (market cap $1.78B). The key difference: Bank of America Corp is far larger — about 239× Recursion Pharmaceuticals Inc's market cap, and Bank of America Corp pays a 1.85% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BAC | RXRX | |
|---|---|---|
Market Cap | $425.43B | $1.78B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $60.62 | $6.79 |
52-Week Low | $44.92 | $2.84 |
Dividend Yield | 1.85% | — |
Enterprise Value | — | $1.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $59.50, down 0.28% today, with a bullish technical outlook and strong fundamental support. The stock shows consistent earnings beats, with Q2 2026 EPS of $1.21 exceeding the $1.13 estimate. Revenue growth accelerated to $113.1 billion in 2025, and the P/E ratio of 14 remains attractive. Recent news highlights strategic partnerships and hiring initiatives, reinforcing long-term growth prospects.
BAC presents a favorable investment case with solid profitability, a 64.8% analyst buy rating, and a consensus price target of $63.79 offering 7.2% upside. Risks include sensitivity to interest rates and macroeconomic volatility, but the bank's deposit franchise and capital flexibility provide resilience. The stock is well-positioned for steady appreciation amid supportive technicals and fundamental strength.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
